The Pershing Square Foundation Announces Its 2026 Lotus Award Recipients

Key Takeaways

• Eight scientists receive $6M for ovarian‑cancer research
• Program targets early detection, immunotherapy, metabolic pathways
• CAR‑T therapy uses umbilical‑cord gamma‑delta T cells
• Engineered probiotics deliver drugs directly to tumors
• Study aims to predict risk in BRCA carriers post‑prophylaxis

Pulse Analysis

Ovarian cancer remains the most lethal gynecologic malignancy, yet it has historically attracted a fraction of the research dollars allocated to other cancers. With roughly 80% of cases diagnosed at an advanced stage, the lack of early‑detection tools and limited therapeutic options have kept survival rates stagnant. The Pershing Square Foundation’s Lotus Award seeks to correct this imbalance by dedicating $6 million to innovative, interdisciplinary projects that could reshape the treatment landscape.

The awardees represent a cross‑section of cutting‑edge science. At Duke, researchers are engineering off‑the‑shelf CAR‑T cells derived from umbilical‑cord gamma‑delta T cells to target citrullinated vimentin, a marker unique to ovarian tumors. Columbia’s team is developing probiotic bacteria that home to tumors and release immune‑stimulating agents on site, while UMass investigators are probing the RNA‑modifying enzyme METTL3 as a chemo‑resistance driver. Other projects explore metabolic reprogramming, novel immune antigens, and precision risk prediction for BRCA mutation carriers, illustrating the breadth of strategies being funded.

Beyond the immediate scientific impact, the Lotus Award signals a broader shift toward targeted philanthropy in women’s health. By leveraging the Pershing Square Sohn Cancer Research Alliance network, the foundation amplifies collaboration across academia and industry, potentially accelerating clinical translation. As private foundations increasingly fill funding gaps left by traditional grant agencies, initiatives like this could catalyze a new wave of breakthroughs, ultimately improving outcomes for the millions of women facing ovarian cancer.